<DOC>
	<DOCNO>NCT01824199</DOCNO>
	<brief_summary>If CYP2C19 genotype predict efficacy heal erosive esophagitis gastric acid secretion patient take day omeprazole .</brief_summary>
	<brief_title>CYP2C19 Genotype Predictor Gastric Acid Suppression</brief_title>
	<detailed_description>Proton pump inhibitor metabolize CYP2C19 hepatic enzyme system . Several variant genotype enzyme exist may lead decreased , normal increase metabolism proton pump inhibitor . With alteration metabolism , degree gastric acid suppression achieve efficacy treat reflux could affect . For example , Asian population low activity CYP2C19 , commonly need low dos proton pump inhibitor manage gastroesophageal reflux sustain blood level availability drug . Theoretically , patient rapid metabolizers would receive less effective treatment proton pump inhibitor</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Inclusion criterion : Age 18 old Have either mildtomoderate Los Angeles ( LA ) Classification System grade B , moderately severe LA grade C , severe LA grade D erosive reflux esophagitis Or patient clinically indicate pH/impedance monitoring proton pump inhibitor therapy indication gastroesophageal reflux disease . Exclusion criterion : Neoplasm esophagus stomach Use drug interfere CYP2C19 metabolism Diazepam , phenytoin , amitriptyline , clomipramine , clopidogrel Cyclophosphamide , progesterone , fluoxetine , fluvoxamine , ketoconazole Lansoprazole , omeprazole , ticlopidine Evidence active H. pylorus infection Inability read due : Blindness , cognitive dysfunction , English language illiteracy Disorders predispose unreliable response Schizophrenia , Alzheimer 's disease significant memory loss</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Esophagitis</keyword>
</DOC>